# A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures

> **NCT00387686** · PHASE2,PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 367 (actual)

## Conditions studied

- Fractures

## Interventions

- **DRUG:** rhBMP-2/CPM
- **DRUG:** rhBMP-2/CPM
- **DRUG:** rhBMP-2/CPM
- **DRUG:** rhBMP-2/CPM

## Key facts

- **NCT ID:** NCT00387686
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2009-07
- **Final completion:** 2010-03
- **Target enrollment:** 367 (ACTUAL)
- **Why stopped:** Decision was taken by Wyeth Sr. Management to early terminate the 3100N7-210 study (terminate enrollment but complete follow-up).
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387686, "A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00387686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*